Mendelspod

Mendelspod

Home
Archive
About
From DNA to Proteins: Illumina Makes Its Proteomics Play - with Krishna Morampudi
Illumina has just made a bold move into proteomics.
 • 
Theral Timpson
16:47
Theranos Had the Vision. Truvian Has the Execution. Our Chat with CEO Jay Srinivasan
On today’s debut interview with Truvian Health, CEO Jay Srinivasan lays out the company’s bold but grounded plan to radically decentralize blood…
 • 
Theral Timpson
35:45
Physicians Don't Want a Laundry List of Genes says Premal Shah, CEO of Myome
Premal Shah says that many companies in personal genomics have emphasized quantity over quality.
 • 
Theral Timpson
40:25
The Customer Case for iconPCR with Stefan Green and Yann Jouvenot
A few weeks back we featured a next gen PCR technology called iconPCR that carries the promise to dramatically impact research.
 • 
Theral Timpson
35:57

September 2025

Alex Dickinson on Long Read Sequencing, Multi Omics, and the Next Frontier in Genomics
Alex Dickinson, former Illumina executive and now host of The Geonomics Podcast, joins us for a wide-ranging conversation on the state of DNA sequencing…
 • 
Theral Timpson
32:12
Rapid Answers for Rare Disease: Katherine Stueland on GeneDx’s Mission
In a time when many diagnostics companies are struggling, GeneDx is thriving by focusing squarely on solving one of medicine’s most pressing problems…
 • 
Theral Timpson
35:51
Moran Snir's Vision for Making Genomic Care Routine across the U.S.
Few founders get to build the future of genomics twice—Moran Snir is doing it a fourth time.
 • 
Theral Timpson
40:27
How Certis Is Rewriting Cancer Models with CEO Peter Ellman
The story of Certis Oncology begins with a patient. In 2012, Barney Berglund was diagnosed with a rare sarcoma. Standard treatments failed him, and…
 • 
Theral Timpson
38:30
Myriad’s Next Chapter: New CEO Sam Raha on Growth, AI, and MRD Testing
For his first interview as CEO of Myriad Genetics, Sam Raha joined us to help kick off Mendelspod’s 15th season.
 • 
Theral Timpson
38:12
Next-Gen MRD Testing: Foresight’s Leap in Sensitivity with Jake Chabon and Dave Kurtz
Catching a cancer relapse before any scan could see it is the ultimate goal for minimal residual disease or MRD testing.
 • 
Theral Timpson
29:40
Bodour Salhia and Danielle Goldberg: Rethinking Cancer Research with Illumina's 5-Base Solution
Epigenetics has emerged as one of the most revealing windows into cancer biology.
 • 
Theral Timpson
26:30
Reinventing PCR: Pranav Patel, N6 Tec
Listen now (30 mins) | Reinventing PCR, huh? That’s what we asked Pranav Patel, CEO and co-founder of N6 Tec, on today’s show.
 • 
Theral Timpson
30:27
© 2025 Theral Timpson
Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture